title: TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro.
abstract: TAK-220 is a CCR5 antagonist, part of the new class of anti-human immunodeficiency virus type 1 (anti-HIV-1) entry inhibitors. We evaluated the anti-HIV-1 interactions between TAK-220 and various antiretrovirals in vitro. Synergy was observed with all drugs at the 90 and 95% inhibitory concentrations. The favorable drug interactions observed suggest that further clinical evaluation is warranted.
authors.affiliation: Massachusetts General Hospital, 65 Landsdowne St., Room 419, Cambridge, MA 02139, USA. mshirsch@partners.org
authors.forename: Cécile L
authors.initials: CL
authors.lastname: Tremblay
authors.forename: Françoise
authors.initials: F
authors.lastname: Giguel
authors.forename: Yongbiao
authors.initials: Y
authors.lastname: Guan
authors.forename: Ting-Chao
authors.initials: TC
authors.lastname: Chou
authors.forename: Katsunori
authors.initials: K
authors.lastname: Takashima
authors.forename: Martin S
authors.initials: MS
authors.lastname: Hirsch
mesh_terms: D019380:Anti-HIV Agents / Q000494:pharmacology*; D065100:CCR5 Receptor Antagonists; D004357:Drug Synergism; D015658:HIV Infections / Q000821:virology; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000821:virology; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology*
chemical_list: D019380:Anti-HIV Agents; D065100:CCR5 Receptor Antagonists; D018894:Reverse Transcriptase Inhibitors